Aveta Biomics Overview
- Year Founded
-
2014
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$4.46M
Aveta Biomics General Information
Description
Developer of nature-inspired drugs designed to provide a durable response to cancer patients. The company's drugs use botanical extracts and are based on the judicious combination of botanical molecules that can simultaneously modulate a network of multiple targets that are likely to be effective, enabling medical professionals to have access to effective and safe drugs to both treat and prevent cancers.
Contact Information
Website
www.avetabiomics.comCorporate Office
- 110 Great Road
- Suite 302
- Bedford, MA 01730
- United States
Corporate Office
- 110 Great Road
- Suite 302
- Bedford, MA 01730
- United States
Aveta Biomics Timeline
Aveta Biomics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC | 19-Mar-2025 | $4.46M | Completed | Clinical Trials - Phase 2 | ||
| 2. Later Stage VC (Series B) | 23-Feb-2022 | Completed | Clinical Trials - Phase 2 | |||
| 1. Early Stage VC (Series A) | 15-Mar-2018 | $1.1M | $1.1M | Completed | Clinical Trials - Phase 2 |
Aveta Biomics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Aveta Biomics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aveta Biomics Patents
Aveta Biomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220193177-A1 | Methods and compositions for treating dysbiosis of oral microbiome | Pending | 01-Apr-2019 | ||
| EP-3946393-A4 | Methods and compositions for treating dysbiosis of oral microbiome | Pending | 01-Apr-2019 | ||
| EP-3946393-A1 | Methods and compositions for treating dysbiosis of oral microbiome | Pending | 01-Apr-2019 | ||
| US-20210252097-A1 | Polypharmaceutical drug compositions and related methods | Active | 02-Apr-2018 | ||
| EP-3773654-A4 | Polypharmaceutical drug compositions and related methods | Active | 02-Apr-2018 | A61K36/9066 |
Aveta Biomics FAQs
-
When was Aveta Biomics founded?
Aveta Biomics was founded in 2014.
-
Where is Aveta Biomics headquartered?
Aveta Biomics is headquartered in Bedford, MA.
-
What industry is Aveta Biomics in?
Aveta Biomics’s primary industry is Drug Discovery.
-
Is Aveta Biomics a private or public company?
Aveta Biomics is a Private company.
-
What is Aveta Biomics’s current revenue?
The current revenue for Aveta Biomics is .
-
How much funding has Aveta Biomics raised over time?
Aveta Biomics has raised $6.16M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
